The European Specialist Nurses Organisation has launched 7 new translations of its guide to the management of switches between reference biologics and biosimilars.
The European Specialist Nurses Organisation (ESNO) has launched 7 new translations of its guide to the management of switches between reference biologics and biosimilars. In addition to the original version in English, the guide is now available in German, French, Spanish, Polish, Italian, Portuguese, and Dutch.
The translations of the guide are available to be downloaded at ESNO’s website and are also made available in hard copy by the ESNO office.
Ber Oomen, executive director at ESNO, said in a statement announcing the translations, “Nurses play a very important role in guiding a patient through their treatment path. Our aim with the guide was to empower the nurse in their interactions with their patients. By translating the guide in to 7 additional languages, we aim to educate even more of the nursing community by providing the information in their language.”
The guide, which was originally launched last year, addresses the specific role of the specialized nurse in interacting with patients during the switching process.
The guide is built on existing European Commission guidelines for the healthcare community, and it emphasizes the nurse’s key link between the prescriber and patient and role in treatment adherence.
The included in the guide are definitions of biologic and biosimilar medicines, information about switching and substitution, information on the benefits of using biosimilars, information on the nurse’s role in managing the switch, pharmacovigilance guidance, case studies, real-world evidence, and flow charts that describe how the switch, follow-up, and support processes will unfold for patients.
The ENSO has previously indicated that the guide will eventually be translated into 23 EU languages.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.